SCHEMBL6498069

SCHEMBL6498069

Cc1ccc(C(=O)Nc2ccc(NCCc3ccccn3)cc2)c(-c2ccccc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC7 Q8WUI4 1/20 0.49
CTNNB1 P35222 2/20 0.48
TCF7L2 Q9NQB0 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
SMO Q99835 1/20 0.46
GCGR P47871 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
HTT P42858 2/20 0.45
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.44
CYP3A4 P08684 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489227 0.96 CTNNB1 (0.48) HDAC7CTNNB1TCF7L2SMN1; SMN2GCGR
SCHEMBL6488546 0.93 CTNNB1 (0.54) CTNNB1TCF7L2SMN1; SMN2GCGRL3MBTL1
SCHEMBL6501757 0.92 GCGR (0.54) CTNNB1TCF7L2SMN1; SMN2GCGRRAB9A
SCHEMBL6492508 0.92 SMN1; SMN2 (0.52) CTNNB1TCF7L2SMN1; SMN2SMOL3MBTL1
Hydrochloric Acid SCHEMBL7079728 0.91 SMN1; SMN2 (0.51) CTNNB1TCF7L2SMN1; SMN2SMOL3MBTL1
SCHEMBL6488178 0.91 SMO (0.52) CTNNB1TCF7L2SMO
SCHEMBL6489454 0.91 MAOA (0.46) CTNNB1TCF7L2SMN1; SMN2GCGRL3MBTL1
SCHEMBL6501333 0.91 RAB9A (0.59) CTNNB1TCF7L2SMN1; SMN2RAB9ANPC1
SCHEMBL6496376 0.89 CNR1 (0.51) CTNNB1TCF7L2SMN1; SMN2GCGRL3MBTL1
SCHEMBL6498735 0.89 RAB9A (0.46) CTNNB1TCF7L2SMN1; SMN2SMOL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 HDAC7 876/4885CTNNB1 1793/4885TCF7L2 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.